{
    "name": "sodium phenylbutyrate/taurursodiol",
    "comment": "Rx",
    "other_names": [
        "Relyvrio"
    ],
    "classes": [
        "Neurologics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/relyvrio-sodium-phenylbutyrate-taurursodiol-4000269",
    "pregnancy": {
        "common": [
            "No data are available for use in pregnant females to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration to rats during pregnancy and lactation exhibited increased offspring mortality at all doses tested, which were less than or like clinical doses "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of sodium phenylbutyrate or taurursodiol in human milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "Each initial daily dosage of 1 packet contains 464 mg of sodium; each maintenance dosage of 2 packets daily contains 928 mg of sodium; consider the daily sodium intake in patients sensitive to salt intake (eg, those with heart failure, hypertension, or renal impairment) and monitor appropriately"
            ],
            "specific": [
                {
                    "type": "Risk with enterohepatic circulation disorders, pancreatic disorders, or intestinal disorders",
                    "description": [
                        "Taurursodiol is a bile acid ",
                        "May increase risk of worsening diarrhea in patients with disorders that interfere with bile acid circulation; monitor appropriately ",
                        "Pancreatic insufficiency, intestinal malabsorption, or intestinal diseases may alter bile acid concentration and may lead to decreased absorption of sodium phenylbutyrate/taurursodiol ",
                        "Owing to different enterohepatic circulation, pancreatic and intestinal disorders have varying degrees of severity; consider consulting with specialist",
                        "Enterohepatic circulation disorders (eg,, biliary infection, active cholecystitis), severe pancreatic disorders (eg, pancreatitis), and intestinal disorders that may alter bile acid concentrations (eg, ileal resection, regional ileitis) were not studied; inform patients with such conditions about risks and benefits with use and advise to notify their healthcare provider if new or worsening diarrhea occurs "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "In in vitro studies show sodium phenylbutyrate/taurursodiol",
                        "Induces CYP1A2, CYP2B6, and CYP3A4 at clinically relevant concentrations ",
                        "Inhibits CYP2C8 and CYP2B6 at clinically relevant concentrations ",
                        "Inhibits OAT1, P-gP, and BCRP at clinically relevant concentrations ",
                        "Substrate of OATP1B3, MATE2-K, OAT3, and BSEP ",
                        "Bile acid sequestering agents",
                        "Avoid use; consider alternative cholesterol lowering agents",
                        "Bile acid sequestering agents (eg, cholestyramine, colestipol, colesevelam) may interfere with taurursodiol absorption ",
                        "Bile acid transport inhibitors",
                        "Avoid use of strong bile salt export pump (BSEP) inhibitors (eg, cyclosporine)",
                        "If coadministration is necessary, exercise caution and monitor serum ALT/AST and bilirubin ",
                        "Medications that inhibit canalicular membrane bile acid transporters such as BSEP may exacerbate accumulation of conjugated bile salts in liver and result in clinical symptoms",
                        "Aluminum-based antacids",
                        "Avoid use and consider alternants",
                        "Aluminum-based antacids have been shown to adsorb bile acids in vitro and may interfere with taurursodiol absorption ",
                        "Probenecid",
                        "Avoid use",
                        "Probenecid may affect renal excretion of sodium phenylbutyrate metabolites",
                        "Pan-histone deacetylase (HDAC) inhibitors",
                        "Avoid coadministration with other HDAC inhibitors ",
                        "OATP1B3 inhibitors",
                        "Avoid use ",
                        "OATP1B3 inhibitors may increase sodium phenylbutyrate/taurursodiol ",
                        "Sensitive OAT1 substrates ",
                        "Avoid coadministration with sensitive OAT1 substrates ",
                        "Sodium phenylbutyrate/taurursodiol may increase plasma concentrations of OAT1 substrates ",
                        "Sensitive P-glycoprotein (P-gP) and Breast Cancer Resistance Protein (BCRP) substrates",
                        "Avoid coadministration with sensitive P-gP and BCRP substrates",
                        "Sodium phenylbutyrate/taurursodiol may increase plasma concentrations of P-gP and BCRP substrates",
                        "CYP2C8, CYP1A2, CYP2B6, and CYP3A4 substrates",
                        "Avoid coadministration of sensitive substrates of CYP2C8, CYP1A2, CYP2B6, and CYP3A4",
                        "Sodium phenylbutyrate/taurursodiol may change plasma concentrations of substrates for these enzymes "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "25"
        },
        {
            "name": "Abdominal pain",
            "percent": "21"
        },
        {
            "name": "Nausea",
            "percent": "18"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "18"
        },
        {
            "name": "Fatigue",
            "percent": "12"
        },
        {
            "name": "Salivary hypersecretion",
            "percent": "11"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        }
    ]
}